Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
National Jewish Health currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are both within 1 distinct art unit. This indicates that the company's applications are being reviewed by different individuals within the same specialized administrative group. The concentration within 1 art unit suggests a high degree of technical similarity between the pending matters.
JESSICA MARIE PRIEST is the busiest examiner for the portfolio, handling 1 pending office action. Given that the total pending office actions is 2 and the busiest examiner pending count is 1, the workload is divided between the 2 distinct examiners. This distribution shows that no single examiner has a dominant role in the company's current prosecution. For a practitioner, this means that prosecution strategies must be tailored to the specific expectations of 2 different examiners within the same Biotechnology & Pharmaceuticals art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALABI, OYELEYE A | 1 | 84.0% | +25.2% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044349 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES OR CONDITIONS RELATED TO INNATE LYMPHOID CELLS | HAMA, JOANNE | 70d |
| 18586007 | Methods of Identifying Atopic Dermatitis and Food Allergies | ALABI, OYELEYE A | — |
| 18412165 | Methods and Compositions for Treating Mucus Obstruction in Severe Asthma | PRIEST, JESSICA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044349 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES OR CONDITIONS RELATED TO INNATE LYMPHOID CELLS | HAMA, JOANNE | 70d |
| 18586007 | Methods of Identifying Atopic Dermatitis and Food Allergies | ALABI, OYELEYE A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18586007 | Methods of Identifying Atopic Dermatitis and Food Allergies | ALABI, OYELEYE A | — | §101§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18412165 | Methods and Compositions for Treating Mucus Obstruction in Severe Asthma | PRIEST, JESSICA MARIE | — | §102§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18044349 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES OR CONDITIONS RELATED TO INNATE LYMPHOID CELLS | HAMA, JOANNE | 1645 | §102§103 | Non-Final OA | 70d | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial